Back to top
more

Chemed (CHE)

(Delayed Data from NYSE)

$584.89 USD

584.89
60,722

-1.28 (-0.22%)

Updated Sep 3, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (52 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Chemed (CHE) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of 5.71% and 2.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

VITUS to Hurt Chemed (CHE) Q1 Earnings, Roto-Rooter to Aid

by Zacks Equity Research

The federal government's recent approach in terms of relaxing regulations, allowing broader use of telehealth, is likely to have helped in some sort of recovery of Chemed's (CHE) VITAS business in Q1.

Moving Average Crossover Alert: Chemed Corp (CHE)

by Zacks Equity Research

Chemed Corporation (CHE) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Why Is Chemed (CHE) Down 2.6% Since Last Earnings Report?

by Zacks Equity Research

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Chemed (CHE) Q4 Earnings Miss Estimates, 2021 Outlook Dull

by Zacks Equity Research

Chemed's (CHE) fourth-quarter 2020 revenues increased 2.1% year over year to $533.3 million.

Trina Mukherjee headshot

3 Outpatient Home Health Stocks Set to Ride the Industry's Upturn

by Trina Mukherjee

Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role should drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE and USPH are well positioned to gain from the prospects.

    DVA vs. CHE: Which Stock Is the Better Value Option?

    by Zacks Equity Research

    DVA vs. CHE: Which Stock Is the Better Value Option?

    Align (ALGN) Rides on Robust Invisalign Sales Amid Coronavirus

    by Zacks Equity Research

    Align Technology's (ALGN) Invisalign clear aligner has been receiving positive feedback and holds huge long-term market potential.

    CVS Health's (CVS) Front Store Sales Robust, LTC Suffers

    by Zacks Equity Research

    CVS Health's (CVS) Health Care Benefits arm benefits from strong Medicare annual enrollment period.

    Quest Diagnostics (DGX) Ties Up With Hackensack Meridian Health

    by Zacks Equity Research

    Quest Diagnostics (DGX) collaborates with Hackensack Meridian Health to manage laboratory operation and provide high-quality healthcare network.

    Here's Why You Should Hold onto NEOGEN (NEOG) Stock for Now

    by Zacks Equity Research

    Investors continue to be optimistic about NEOGEN (NEOG) on robust segmental and geographical growth.

    Encompass Health (EHC) to Spin Off Unit to Streamline Business

    by Zacks Equity Research

    Encompass Health (EHC) is exploring strategic alternatives to split its home health and hospice business from the original corporate structure to streamline operations.

    DVA vs. CHE: Which Stock Is the Better Value Option?

    by Zacks Equity Research

    DVA vs. CHE: Which Stock Is the Better Value Option?

    DVA or CHE: Which Is the Better Value Stock Right Now?

    by Zacks Equity Research

    DVA vs. CHE: Which Stock Is the Better Value Option?

    Looking for a Growth Stock? 3 Reasons Why Chemed (CHE) is a Solid Choice

    by Zacks Equity Research

    Chemed (CHE) possesses solid growth attributes, which could help it handily outperform the market.

    Chemed (CHE) Moves to Buy: Rationale Behind the Upgrade

    by Zacks Equity Research

    Chemed (CHE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    Encompass Health (EHC) to Build Rehabilitation Hub in Illinois

    by Zacks Equity Research

    Encompass Health (EHC) to construct an inpatient rehabilitation hospital with a capacity of 40 in Shiloh Illinois, which will be run as a joint venture with BJC HealthCare.

    DVA vs. CHE: Which Stock Should Value Investors Buy Now?

    by Zacks Equity Research

    DVA vs. CHE: Which Stock Is the Better Value Option?

    Is Chemed (CHE) a Solid Growth Stock? 3 Reasons to Think " Yes "

    by Zacks Equity Research

    Chemed (CHE) could produce exceptional returns because of its solid growth attributes.

    Chemed's (CHE) Shares Up on Q3 Earnings and Revenue Beat

    by Zacks Equity Research

    Chemed (CHE) reports solid revenue growth across key subsidiaries in third-quarter results.

    Chemed (CHE) Beats Q3 Earnings and Revenue Estimates

    by Zacks Equity Research

    Chemed (CHE) delivered earnings and revenue surprises of 21.80% and 2.17%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

    Healthcare Stock Q3 Earnings Due on Oct 29: NVCR, CRL & More

    by Zacks Equity Research

    Coronavirus is going to affect the earnings results of healthcare players. While hospitals and health insurers might have suffered the COVID-19 impact, others providing virtual care and COVID-19-related services are likely to have gained from the same.

    Chemed (CHE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    by Zacks Equity Research

    Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    DVA vs. CHE: Which Stock Should Value Investors Buy Now?

    by Zacks Equity Research

    DVA vs. CHE: Which Stock Is the Better Value Option?

    DVA vs. CHE: Which Stock Is the Better Value Option?

    by Zacks Equity Research

    DVA vs. CHE: Which Stock Is the Better Value Option?